Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Vabysmo (faricimab-svoa) is a bispecific monoclonal antibody indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It uniquely targets and inhibits both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), two key pathways involved in retinal vascular leakage, inflammation, and neovascularization. By simultaneously blocking VEGF-A and Ang-2, Vabysmo helps to improve and maintain vision, reduce macular edema, and extend treatment intervals compared to anti-VEGF monotherapy.
Fact Table | |
Formula | C6544H10014N1734O2030S46 |
License | US FDA (2022) |
Bioavailability | Intravitreal – local ocular effect |
Legal status | Prescription only |
Chemical Name | Faricimab |
Elimination half-life | ~7.5 days (ocular) |
Dosage (Strength) | 6 mg/0.05 mL solution for intravitreal injection |
Pregnancy | Category C – Risk not ruled out |
Brands | Vabysmo |
Protein binding | High (IgG1-based monoclonal antibody) |
PubChem CID | 162201054 |
MedlinePlus | a622065 |
ChEBI | Not assigned |
ATC code | S01LA08 |
DrugBank | DB16608 |
KEGG | D12349 |
Routes of administration | Intravitreal injection |
Vabysmo is administered by intravitreal injection under sterile conditions by an ophthalmologist.
Each vial is for single-use only. Treatment schedules should be guided by visual acuity and retinal anatomical outcomes as assessed by clinical imaging.
Active ingredient: faricimab-svoa (6 mg/0.05 mL) Inactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, polysorbate 20, and sucrose in water for injection. The solution is preservative-free and should be refrigerated.
Vabysmo is contraindicated in patients with:
Patients should be monitored for endophthalmitis, retinal detachment, and increased intraocular pressure following injection. Use with caution in patients with a history of stroke, arterial thromboembolic events, or other cardiovascular risks, as systemic VEGF inhibition may contribute to thromboembolic complications. Repeated intraocular injections carry a risk of ocular complications; proper aseptic technique is essential.
Common side effects may include:
Less common but serious side effects include: